Redirecting to https://www.prnewswire.com/apac/news-releases/sacituzumab-tirumotecan-sac-tmt-in-combination-with-pembrolizumab-for-first-line-treatment-of-pd-l1-positive-nsclc-published-in-the-lancet-302786271.html